Huiyu Pharmaceutical announced that Seacross Pharma Ltd., a subsidiary of the company, recently received marketing permits for injectable dicetabine and zoledronic acid injections approved and issued by the Italian Medicines Administration and the Portuguese National Drug and Medical Products Administration. Currently, dicetabine for injection has been approved for marketing in 5 countries, zoledronic acid injections have been approved for marketing in 6 countries, and registration applications for both products have been submitted in Germany. This approval will help enrich the company's product pipeline in the international market, and will not have a significant impact on business performance in the short term.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.